alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 70.11 Related substances. ( a ) Different color additives may cause similar or related pharmacological or biological effects, and, in the absence of evidence to the contrary, those that do so will be considered to have additive toxic effects.
( b ) Food additives may also cause pharmacological or biological effects similar or related to such effects caused by color additives, and, in the absence of evidence to the contrary, those that do so will be considered as having additive toxic effects.
( c ) Pesticide chemicals may also cause pharmacological or biological effects similar or related to such effects caused by color additives, and, in the absence of evidence to the contrary, those that do so will be considered to have additive toxic effects.
( d ) In establishing tolerances for color additives, the Commissioner will take into consideration, among other things, the amount of any common component permitted in other color additives, in food additives, and in pesticide chemical residues as well as the similar biological activity (such as cholinesterase inhibition) produced by such substance.
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1230 Fiberoptic oximeter catheter. ( a ) *Identification.* A fiberoptic oximeter catheter is a device used to estimate the oxygen saturation of the blood. It consists of two fiberoptic bundles that conduct light at a desired wavelength through blood and detect the reflected and scattered light at the distal end of the catheter.
( b ) *Classification.* Class II (performance standards).
EE-RM-STD-00-100 COMMENT 06B

Deprurt~ntofEne~ 

Energy Efficiency Program for Commercial and Industrial Equip~nt: 

Efficiency Standards for Co~rcial HV AC and Water Heating Products 

9:00 - 9:05 am 

9:05 - 9:15 am 

9: 15 - 9:30 am 

9:30 - 10:15 am 

10: 15 - 10:30 am 

10:30 - 12:30 noon 

12:30 - 1 :30 pm 

1:30 - 3:00 pm 

3:00 - 3:15 pm 

3: 15 - 4:30 pm 

4:30 - 4:45 pm 

4:45 - 5:00 pm 

5:00pm 

Public Workshop Agenda 

July 11, 2000 

Opening - Cyrus N asseri 

Agenda Review and Overview - Doug Brookman 

DOE Process and Inclinations - Cyrus Nasseri 

Brief Opening Statements by Stakeholders 

Break 

Commercial Product Screening Analysis - Presentation by PNNL, 

Comments by Stakeholders, and Discussion 

• Methodology 

• Results and Interpretations 

• Product Categories not included in the Analysis 

Lunch - (on your own) 

DOE Inclinations based on the Screening Analysis - Presentation by 

Cyrus Nasseri, Comments by Stakeholders, and Discussion 

• Adopt ASHRAE 90.1-1999 energy efficiency levels (20 

products) 

• Conduct further analyses (9 products) 

• Suggest ASHRAE addenda (4 products) 

• Retain current EPCA energy efficiency levels (1 product) 

Break 

Future Analytical Issues 

Next Steps - Cyrus Nasseri 

Closing 

Adjourn
<PAGE>   1
                                                              EXHIBIT 10.4.1


     RECOGNITION AND RETENTION PLAN
        FOR OUTSIDE DIRECTORS OF
       TAPPAN ZEE FINANCIAL, INC.

       (Adopted on March 25, 1996
     Effective as of July 11, 1996)


                AMENDMENT





1.   Article V - Effective as of July 11, 1996, the first sentence of section
5.3(a) shall be amended and restated to read in its entirety as follows:

                  Any cash dividends or distributions declared and paid with
                  respect to Shares in the Trust Fund that are, as of the record
                  date for such dividend, allocated to an Eligible Director in
                  connection with an Award shall be held in the Trust Fund and
                  distributed to such Eligible Director (with any earnings
                  attributable thereto) at the same time as the related Shares.


2.   Article VI - Effective as of July 11, 1996, the first clause of section
5.6(a)(ii) shall be amended by replacing the words "prior to October 5, 1996"
with the words "under the Plan."


3.   Article VII - Effective as of July 11, 1996, section 7.3 shall be amended 
by adding the following new subsection "(c)" which shall read in its entirety as
follows:

                           (c)     Nothing in this section 7.3 shall be deemed 
                  to change the otherwise applicable vesting schedule for any
                  Eligible Director.


                                   Page 1 of 1
###### Editorial Note on Part 181

#### Editorial Note:

Nomenclature changes to part 181 appear at 61 FR 14482, Apr. 2, 1996, and 66 FR 56035, Nov. 6, 2001.

#### § 181.24 Antioxidants.

Substances classified as antioxidants, when migrating from food-packaging material (limit of addition to food, 0.005 percent) shall include:

Butylated hydroxyanisole.

Butylated hydroxytoluene.

Dilauryl thiodipropionate.

Distearyl thiodipropionate.

Gum guaiac.

Nordihydroguairetic acid.

Propyl gallate.

Thiodipropionic acid.

2,4,5-Trihydroxy butyrophenone.

[42 FR 14638, Mar. 15, 1977; 42 FR 56728, Oct. 28, 1977]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5440 *Beta*-2-glycoprotein III immunological test system. ( a ) *Identification.* A *beta*-2-glycoprotein III immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the *beta*-2-glycoprotein III (a serum protein) in serum and other body fluids. Measurement of *beta*-2-glycoprotein III aids in the diagnosis of an inherited deficiency of this serum protein and a variety of other conditions.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 65 FR 2312, Jan. 14, 2000]
[Federal Register Volume 75, Number 41 (Wednesday, March 3, 2010)]
[Notices]
[Page 9587]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4324]


=======================================================================
-----------------------------------------------------------------------

COMMISSION OF FINE ARTS


Notice of Meeting

    The next meeting of the U.S. Commission of Fine Arts is scheduled 
for 18 March 2010, at 10 a.m. in the Commission offices at the National 
Building Museum, Suite 312, Judiciary Square, 401 F Street, NW., 
Washington DC, 20001-2728. Items of discussion may include buildings, 
parks and memorials.
    Draft agendas and additional information regarding the Commission 
are available on our Web site: http://www.cfa.gov. Inquiries regarding 
the agenda and requests to submit written or oral statements should be 
addressed to Thomas Luebke, Secretary, U.S. Commission of Fine Arts, at 
the above address; by e-mailing <a href="/cdn-cgi/l/email-protection#7e0d0a1f18183e1d181f50191108"><span class="__cf_email__" data-cfemail="601314010606200306014e070f16">[email protected]</span></a>; or by calling 202-504-
2200. Individuals requiring sign language interpretation for the 
hearing impaired should contact the Secretary at least 10 days before 
the meeting date.

    Dated: February 24, 2010 in Washington DC.
Thomas Luebke,
AIA Secretary.
[FR Doc. 2010-4324 Filed 3-2-10; 8:45 am]
BILLING CODE 6330-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit








AMENDMENT TO THE 
SWIFT ENERGY COMPANY
2016 EQUITY INCENTIVE PLAN


This Amendment (the “Amendment”) to the Swift Energy Company 2016 Equity Incentive Plan (the “Plan”), is made effective as of May 5, 2017 (the “Amendment Effective Date”).  Capitalized terms used but not defined herein shall have the meanings assigned to them in the Plan.


WHEREAS, Swift Energy Company previously adopted the Plan; 
WHEREAS, Swift Energy Company changed its name to SilverBow Resources, Inc. (“the Company”), effective May 5, 2017; 
WHEREAS, the Board desires to amend the Plan in order to reflect the Company’s name change to “SilverBow Resources, Inc.”
NOW, THEREFORE, BE IT RESOLVED, that, the Plan shall be amended as of the Amendment Effective Date, as set forth below: 


		
	1.
	The Plan should be renamed the “SilverBow Resources, Inc. 2016 Equity Incentive Plan.”’




		
	2.
	Any reference to the “Swift Energy Company 2016 Equity Incentive Plan” within the Plan should be deleted replaced with “SilverBow Resources, Inc. 2016 Equity Incentive Plan.”


    
		
	3.
	Any additional reference to “Swift Energy Company” or “Swift Energy” within the Plan should be deleted and replaced with “SilverBow Resources” 




FURTHER RESOLVED, that, as amended hereby, the Plan is specifically ratified and reaffirmed.




	
		
	SilverBow Resources, Inc.

	



/s/ Sean C. Woolverton
	 

	Sean C. Woolverton 
Chief Executive Officer
	 






    


1
§ 26.69 Monitoring of conformity assessment bodies. The following shall apply with regard to the monitoring of conformity assessment bodies (CAB's) listed in subpart B of this part: ( a ) Designating authorities shall assure that their CAB's listed in subpart B of this part are capable and remain capable of properly assessing conformity of products or processes, as applicable, and as covered in subpart B of this part. In this regard, designating authorities shall maintain, or cause to maintain, ongoing surveillance over their CAB's by means of regular audit or assessment;
( b ) The parties undertake to compare methods used to verify that the CAB's listed in subpart B of this part comply with the relevant requirements of subpart B of this part. Existing systems for the evaluation of CAB's may be used as part of such comparison procedures;
( c ) Designating authorities shall consult as necessary with their counterparts, to ensure the maintenance of confidence in conformity assessment procedures. With the consent of both parties, this consultation may include joint participation in audits/inspections related to conformity assessment activities or other assessments of CAB's listed in subpart B of this part; and
( d ) Designating authorities shall consult, as necessary, with the relevant regulatory authorities of the other party to ensure that all technical requirements are identified and are satisfactorily addressed.
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1370 Catheter tip occluder. ( a ) *Identification.* A catheter tip occluder is a device that is inserted into certain catheters to prevent flow through one or more orifices.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3960 Nucleic acid-based device for the amplification, detection, and identification of microbial pathogens directly from whole blood specimens. ( a ) *Identification.* A nucleic acid-based device for the amplification, detection, and identification of microbial pathogens directly from whole blood specimens is a qualitative in vitro device intended for the amplification, detection, and identification of microbial-associated nucleic acid sequences from patients with suspected bloodstream infections. This device is intended to aid in the diagnosis of bloodstream infection when used in conjunction with clinical signs and symptoms and other laboratory findings.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Premarket notification submissions must include detailed device description documentation, including the device components, ancillary reagents required but not provided, and a detailed explanation of the methodology, including primer/probe sequence, design, and rationale for sequence selection.
( 2 ) Premarket notification submissions must include detailed documentation from the following analytical and clinical performance studies: Analytical sensitivity (limit of detection), reactivity, inclusivity, precision, reproducibility, interference, cross reactivity, carryover, and cross contamination.
( 3 ) Premarket notification submissions must include detailed documentation from a clinical study. The study, performed on a study population consistent with the intended use population, must compare the device performance to results obtained from well-accepted reference methods.
( 4 ) Premarket notification submissions must include detailed documentation for device software, including, but not limited to, software applications and hardware-based devices that incorporate software.
( 5 ) The device labeling must include limitations regarding the need for culture confirmation of negative specimens, as appropriate.
( 6 ) A detailed explanation of the interpretation of results and acceptance criteria must be included in the device's 21 CFR 809.10(b)(9) compliant labeling.
( 7 ) Premarket notification submissions must include details on an end user device training program that will be offered while marketing the device, as appropriate.
( 8 ) As part of the risk management activities performed as part of your 21 CFR 820.30 design controls, you must document an appropriate end user device training program that will be offered as part of your efforts to mitigate the risk of failure to correctly operate the instrument.
[82 FR 47967, Oct. 16, 2017]
Napoleon Gas Fireplaces: BGD34 

IDEALERS I SITE MAP 

Fireplaces Stoves Inserts Mantels Outdoor 

BGD34 Direct Vent Fireplace 

Specifications BGD34 

Fuel 

(Propane Conversion Kit Available) Natural Gas 

BTU Input 

Maximum Heating Efficiency 

(Steady State) 

Blower 

Mobile Home Approved 

Additional Information 

15,000 

78% 

Optional 

Yes 

• Overall depth of 12" makes endless installation 

possibilites with a minimum of space 

• No hearth extension required, saving you space in 

smaller rooms 

• No chimney required - vents through the wall or roof 

• Ground level and above 

• Basement even below grade using a Periscope 

(#GD201) 

• Approved for installation in bathrooms, bedrooms and 

bed-sitting rooms 

• Suitable for mobile home installations 

• Hot air distribution kit optional 

TESTED TO ANSI Z21.SS and CSA 2.33 

Page I of I 

Tech Services What's New Company Where • to Buy 

Features Accessories 

line dimensions are to be used as a guide only. Please consult your 

Installation manual for updated and precise measurements before proceeding 

to install or frame your Napoleon Fireplace. Check all Local and National 

Building Codes and Gas Regulations 

Manual Brochure 

I Fireplaces I Stoves I Inserts I Mantels I Outdoor I Tech Services I What's New I Company I Where to Buy 

Napoleon Gourmet Grills Napoleon Heating and Air Napoleon Waterfalls 

Copyright© 2008 Napoleon@ Fireplaces. All rights reserved. 

EERE-2006-BT-STD-0129 COMMENT 124
Napoleon Gas Fireplaces: BGD34 

IDEALERS I SITE MAP 

Fireplaces Stoves Inserts Mantels Outdoor 

BGD34 Direct Vent Fireplace 

• Up to 15,000 BTU's 

• Heater rated 

• No electricity required to light or operate - millivolt system 

ensures reliable use even during power failures 

• Turn on and off at the flick of a switch 

• Available in clean burning, convenient natural gas or propane 

• 50% flame/heat adjustment for maximum comfort and 

efficiency 

• Heat transferring high temperature glass (16" x 30 5/8") 

• No conventional chimney required - vents directly through the 

wall 

• Features the 100% SAFE GUARD'M automatic gas shut off for 

your peace of mind 

• Realistic, ceramic fiber, light-weight molded PHAZER® logs 

for a natural wood burning look 

• Zero clearance installations let you frame with standard 2x4's 

• YELLOW DANCING FLAME® burner system 

• President's Limited Lifetime Warranty 

Tech Services What's New Company 

Manual 

I Fireplaces I Stoves I Inserts I Mantels I Outdoor I Tech Services I What's New I Company I Where to Buy 

Napoleon Gourmet Grills Napoleon Heating and Air Napoleon Waterfalls 

Copyright© 2008 Napoleon® Fireplaces. All rights reserved. 

Page 1 of 1 

Where • to Buy 

Brochure 

EERE-2006-BT-STD-0129 COMMENT 124
AFS-13-440-E

August 26, 2013

 Exemption No. 10377A

 Regulatory Docket No. FAA-2011-0892

Mr. Jeffrey J. Jenkins

Chief Inspector, Part 135

PHI, Inc.

P.O. Box 90808

Lafayette, LA 70509

Dear Mr. Jenkins:

This letter is to inform you that we have granted your petition to extend and amend 

Exemption No. 10377. It explains the basis for our decision, describes its effect, and lists the 

conditions and limitations.

The Basis for Our Decision

By letter dated June 25, 2013, you petitioned the Federal Aviation Administration (FAA) on 

behalf of PHI, Inc. (PHI), for an extension to Exemption No. 10377. That exemption from 

§§ 91.411(b) and 91.413(c) of Title 14, Code of Federal Regulations (14 CFR) allows PHI to 

perform air traffic control (ATC) transponder tests and inspections and altimeter system and 

altimeter reporting equipment tests and inspections for its part 119 aircraft maintained under a 

continuous airworthiness maintenance program (CAMP). The exemption also allows PHI to 

perform similar tests and inspections on its part 135 aircraft maintained under an approved 

aircraft inspection program (AAIP).

In your petition, you indicate that there has been no change in the conditions and reasons 

relative to public interest and safety that were the basis for granting the original exemption. 

PHI has requested, however, that it be permitted to accomplish the tests and inspections 

allowed by this exemption when operating outside the United States. We have reviewed the 

corresponding International Civil Aviation Organization (ICAO) Standards and 

Recommended Practices and have identified no differences with the regulation from which 

we grant this exemption. However, a foreign country still may not allow you to operate in 

that country under this exemption if it so chooses.
2

Our Decision

The FAA has determined that the justification for the extension and amendment of 

Exemption No. 10377, remains valid with respect to this exemption and is in the public 

interest. Therefore, under the authority provided by 49 U.S.C. 40113 and 44701, which the 

FAA Administrator has delegated to me, I grant your petition, subject to the following 

conditions and limitations.

Conditions and Limitations 

1. All ATC transponder tests and inspections and all altimeter reporting equipment 

tests and inspections must be conducted under PHI’s part 119 CAMP. 

2. All tests and inspections must be recorded in the aircraft’s maintenance log by the 

person performing each inspection and test. This entry must identify the person, 

the date, and this exemption number.

3. An appropriate record of these tests and inspections also must be kept in PHI’s 

maintenance recording system for part 119 and part 135.

4. PHI may operate outside the U.S. under this exemption, unless otherwise 

prohibited by a foreign country.

The Effect of Our Decision

Our decision extends the termination date of Exemption No. 10377, to October 31, 2015, 

unless sooner superseded or rescinded.

Sincerely,

/s/

Michael J. Zenkovich

Deputy Director, Flight Standards

 Service
**Printed on 100% recycled/recyclable paper with 100% post**  **- consumer fiber and process chlorine free.**  **Customer Service Hotline: 1 -**  **800 -**  **438 -**  **2474** 7/25/2013 The Honorable Rand y C. Huffman Cabinet Secretary West Virginia Department of Environment al Protection 601 57 th Street SE Charleston, West Virginia 25304 Dear Secretary

Huffman: On July 1, 2013, th e U.S. Environmental Protection Agency (E PA) received a revision to the West Virginia S tate I mpl ementation Plan (SI P). The SI P revision was submitted to address required infrastructure elements of Section 110(a)(2) of the Clean Air Act (CAA) which are necessary to implement, maintain, and enforce the 20 10 1

- hour sulfur dioxide N ational A mbient A ir Quality Standards (NAAQS) in West Virginia. EPA has determined that the submittal is complete for these elements, and is reviewing it to prepare a Notice of Proposed Rulemaking (NPR ) action. If members of your staff have an y questions, they may direct them to Ms. Ellen Schmitt, Office of Air Program Planning, at (215) 814

- 5787. Sincerel y, /s/ Diana Esher, Director Air Protection Division cc: John A. Benedict, Director, West Virginia Department of Environmental Protection
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1625 Prolactin (lactogen) test system. ( a ) *Identification.* A prolactin (lactogen) test system is a device intended to measure the anterior pituitary polypeptide hormone prolactin in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of disorders of the anterior pituitary gland or of the hypothalamus portion of the brain.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2308, Jan. 14, 2000]
Editorial Note on Part 314
Editorial Note: Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004; 81 FR 69639, Oct. 6, 2016.

§ 314.161 Determination of reasons for voluntary withdrawal of a listed drug. ( a ) A determination whether a listed drug that has been voluntarily withdrawn from sale was withdrawn for safety or effectiveness reasons may be made by the agency at any time after the drug has been voluntarily withdrawn from sale, but must be made: ( 1 ) Prior to approving an abbreviated new drug application that refers to the listed drug;
( 2 ) Whenever a listed drug is voluntarily withdrawn from sale and abbreviated new drug applications that referred to the listed drug have been approved; and
( 3 ) When a person petitions for such a determination under §§ 10.25(a) and 10.30 of this chapter.
( b ) Any person may petition under §§ 10.25(a) and 10.30 of this chapter for a determination whether a listed drug has been voluntarily withdrawn for safety or effectiveness reasons. Any such petition must contain all evidence available to the petitioner concerning the reason that the drug is withdrawn from sale.
( c ) If the agency determines that a listed drug is withdrawn from sale for safety or effectiveness reasons, the agency will, except as provided in paragraph (d) of this section, publish a notice of the determination in the Federal Register.
( d ) If the agency determines under paragraph (a) of this section that a listed drug is withdrawn from sale for safety and effectiveness reasons and there are approved abbreviated new drug applications that are subject to suspension under section 505(j)(5) of the act, FDA will initiate a proceeding in accordance with § 314.153(b).
( e ) A drug that the agency determines is withdrawn for safety or effectiveness reasons will be removed from the list, under § 314.162. The drug may be relisted if the agency has evidence that marketing of the drug has resumed or that the withdrawal is not for safety or effectiveness reasons. A determination that the drug is not withdrawn for safety or effectiveness reasons may be made at any time after its removal from the list, upon the agency's initiative, or upon the submission of a petition under §§ 10.25(a) and 10.30 of this chapter. If the agency determines that the drug is not withdrawn for safety or effectiveness reasons, the agency shall publish a notice of this determination in the Federal Register. The notice will also announce that the drug is relisted, under § 314.162(c). The notice will also serve to reinstate approval of all suspended abbreviated new drug applications that referred to the listed drug.
[57 FR 17995, Apr. 28, 1992]